Live Analyst Rating Changes 1505 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Ziyi Chen
GS
Ziyi Chen
Wall Street Analyst
★★★★★
#236
on 13Foresight · ranked by our own returns
100%
Success Rate
+34.0%
Average Return
5 of 5 calls profitable · +6.1% vs benchmark
📈 Across the calls we could measure, roughly 100% of Ziyi Chen's ratings turned a profit when each position was held for 1 year — averaging +34.0% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

23 Buy 22 Hold 3 Sell
Ziyi's Stock Coverage 38 ratings · 2026-06-18
Company Date Position Consensus Price Target 1-Yr Return
LEGN
Legend Biotech
May 12, 2026 BUY Strong Buy
+115.9% avg upside
27 analysts
$43.92
31.66% Upside
+26.9%
HK:2359
WuXi AppTec Co., Ltd. Class H
Apr 28, 2026 BUY Strong Buy
+23.2% avg upside
2 analysts
$169.40
38.27% Upside
·
HK:1530
3SBio
Apr 02, 2026 HOLD Buy
+56.1% avg upside
3 analysts
$29.43
83.20% Upside
·
HK:1513
Livzon Pharmaceutical Group
Feb 05, 2026 SELL Strong Sell
-5.3% avg upside
1 analyst
$22.99
5.26% Downside
·
HK:6821
Asymchem Laboratories (Tianjin) Co., Ltd. Class H
Oct 31, 2025 BUY Strong Buy
+14.3% avg upside
2 analysts
$98.40
10.67% Upside
·
HK:2696
Shanghai Henlius Biotech, Inc. Class H
Oct 30, 2025 BUY Strong Buy
+67.3% avg upside
2 analysts
$100.70
69.05% Upside
·
HK:6996
Antengene Corporation Limited
Oct 27, 2025 HOLD Hold
+70.3% avg upside
1 analyst
$5.74
70.30% Upside
·
HK:1672
Ascletis Pharma, Inc.
Oct 27, 2025 HOLD Hold
+29.6% avg upside
1 analyst
$12.84
29.59% Upside
·
HK:1167
Jacobio Pharmaceuticals Group Co., Ltd.
Oct 27, 2025 HOLD Buy
+122.1% avg upside
2 analysts
$9.50
109.74% Upside
·
HK:2256
Abbisko Cayman Limited
Oct 26, 2025 BUY Strong Buy
+150.8% avg upside
3 analysts
$27.10
201.75% Upside
·
HK:2268
WuXi XDC Cayman, Inc.
Oct 17, 2025 HOLD Buy
+56.5% avg upside
2 analysts
$63.30
37.87% Upside
·
HK:2269
Wuxi Biologics (Cayman)
Oct 17, 2025 HOLD Buy
+23.5% avg upside
4 analysts
$33.50
12.10% Upside
·
HK:9969
InnoCare Pharma Ltd.
Oct 09, 2025 BUY Strong Buy
+84.0% avg upside
3 analysts
$22.89
121.06% Upside
·
HK:9989
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H
Sep 03, 2025 SELL Strong Sell
+11.7% avg upside
1 analyst
$4.31
11.72% Upside
·
HK:2186
Luye Pharma Group
Sep 01, 2025 HOLD Hold
+87.8% avg upside
1 analyst
$3.70
87.84% Upside
·
HK:1477
Ocumension Therapeutics
Aug 25, 2025 HOLD Hold
+128.7% avg upside
1 analyst
$10.86
128.65% Upside
·
HK:0867
China Medical System Holdings
Aug 19, 2025 BUY Strong Buy
+62.3% avg upside
2 analysts
$17.92
73.87% Upside
·
HK:3692
Hansoh Pharmaceutical Group Company Limited
Aug 19, 2025 BUY Strong Buy
+32.8% avg upside
5 analysts
$39.93
34.40% Upside
·
HK:6990
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H
Aug 19, 2025 BUY Strong Buy
+20.3% avg upside
3 analysts
$454.04
12.49% Upside
·
HK:2171
CARsgen Therapeutics Holdings Ltd.
Jul 09, 2025 SELL Strong Sell
-4.0% avg upside
1 analyst
$14.92
4.04% Downside
·
HK:1952
Everest Medicines Ltd.
Jul 09, 2025 HOLD Buy
+93.0% avg upside
3 analysts
$64.27
142.58% Upside
·
HK:1801
Innovent Biologics
Jul 09, 2025 BUY Strong Buy
+33.7% avg upside
7 analysts
$96.22
28.62% Upside
·
HK:1093
CSPC Pharmaceutical Group
Jul 09, 2025 BUY Strong Buy
+61.5% avg upside
6 analysts
$9.62
38.79% Upside
·
HK:1177
Sino Biopharmaceutical
Jul 09, 2025 BUY Strong Buy
+75.4% avg upside
6 analysts
$6.19
34.58% Upside
·
HK:1521
Frontage Holdings Corp.
Apr 21, 2025 HOLD Sell
+39.2% avg upside
2 analysts
$1.35
29.84% Upside
·
HK:3933
The United Laboratories International Holdings
Mar 26, 2025 HOLD Hold
+83.3% avg upside
1 analyst
$15.29
83.32% Upside
·
HK:2607
Shanghai Pharmaceuticals Holding Co
Apr 03, 2024 SELL Sell
+21.9% avg upside
2 analysts
$13.44
12.11% Upside
·
HK:1789
AK Medical Holdings Ltd.
Mar 28, 2024 BUY Strong Buy
+28.7% avg upside
2 analysts
$8.90
60.56% Upside
·
ONC
BeOne Medicines
Mar 17, 2024 BUY Strong Buy
+31.0% avg upside
28 analysts
$310.15
17.53% Upside
+57.3%
HK:1548
Genscript Biotech
Mar 12, 2024 BUY Strong Buy
+156.9% avg upside
1 analyst
$28.96
156.92% Upside
·
HK:2196
Shanghai Fosun Pharmaceutical (Group) Co
Oct 31, 2023 HOLD Hold
+62.5% avg upside
1 analyst
$25.60
62.46% Upside
·
ZLAB
Zai Lab
Oct 26, 2023 BUY Strong Buy
+226.5% avg upside
13 analysts
$73.34
313.58% Upside
+40.9%
HK:6160
BeOne Medicines Ltd
Sep 20, 2023 BUY Strong Buy
+49.9% avg upside
2 analysts
$237.34
50.87% Upside
·
HK:2126
JW (Cayman) Therapeutics Co. Ltd.
Aug 30, 2023 BUY Strong Buy
+225.1% avg upside
1 analyst
$5.17
225.13% Upside
·
HK:6622
Zhaoke Ophthalmology Ltd.
Mar 27, 2023 HOLD Hold
+54.2% avg upside
1 analyst
$4.13
54.18% Upside
·
ADAG
Adagene
Sep 29, 2022 BUY Strong Buy
+110.1% avg upside
8 analysts
$7.58
115.99% Upside
+21.4%
LIANY
LianBio Sponsored ADR
Nov 26, 2021 HOLD Buy
+11232.2% avg upside
4 analysts
$18.60
16717.44% Upside
·
SHTDY
Sinopharm Group Co
Mar 19, 2020 BUY Strong Buy
2 analysts
+23.6%
🔒 33 more ratings — with price targets, crowd consensus and our measured returns.
Free account unlocks every analyst's full coverage table.
Ziyi Chen — Frequently Asked Questions
How accurate are Ziyi Chen's stock ratings?
Based on the calls 13Foresight could measure, about 100% of Ziyi's ratings were profitable over a one-year hold, with an average return of +34.0% per rating, or +6.1% versus the S&P 500. We score every analyst the same way, from historical prices.
How is Ziyi ranked on 13Foresight?
Ziyi Chen is currently ranked #236 with a 5-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Ziyi cover?
Ziyi most recently has ratings on LEGN, HK:2359, HK:1530, HK:1513, HK:6821, HK:2696, HK:6996, HK:1672, HK:1167, HK:2256, HK:2268, HK:2269 and 26 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.